Giovannoni G, Rammohan K, Cook S, et al. Proportions of patients with highly active RMS achieving no evidence of disease activity (NEDA) in response to cladribine tablets in CLARITY. ECTRIMS 217, P1143.
Atogepant (Aquipta) vergoed voor preventieve behandeling van therapieresistente chronische migraine
dec 2024 | Hoofdpijn